Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell respo... by Dennis Horvath, Nigel Temperton, Martin Mayora-Neto, Kelly Da Costa, Diego Cantoni, Reinhold Horlacher, Armin Günther, Alexander Brosig, Jenny Morath, Barbara Jakobs, Marcus Groettrup, Heinz Hoschuetzky, Jacques Rohayem, Jan ter Meulen

Get full text